How long does tirzepatide stay within specification at minus 80 °C once reconstituted?

The particulars: tirzepatide · minus 80 °C.

I have read the obvious sources and they disagree with each other, so I would rather ask people who have actually done this.

I have a working setup and a notebook, and I am prepared to be told that my setup is inadequate if that is the answer.

Concretely, what should I do, and how would I know afterwards whether I did it right?

Whatever the refrigerated figure is, freezing does not simply extend it. minus 80 °C is 85 kelvin below a refrigerator, and below the glass transition of a lyophilised cake the ten-degree rule of thumb stops applying at all — solid-state chemistry is not slow liquid chemistry, it is a different regime, and the failure modes that survive it are mechanical rather than chemical. A frozen solution is not a slow solution: ice excludes solute, so the unfrozen fraction concentrates, the pH of the buffer shifts as one component crystallises first, and the damage happens during the transitions rather than during the hold. "Within specification" also needs a specification: purity, content, or both, and at what limit. Without that the question has no numerical answer at all.

The short version: water enables most of it, oxygen enables oxidation, surfaces enable adsorption, and agitation enables aggregation.

Light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.

Degradation pathway by condition

The part that matters: adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.

Deamidation via the succinimide intermediate is well characterised, with sequence-dependent rates highest for asparagine-glycine motifs.

Sequence determines which pathways apply, so general statements are general.

Cold, dry, dark, still. Those four words cover most of the mitigation.

The honest answer is that most reported "degradation" is adsorption and dilution error rather than chemistry.

Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.

A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.

Aggregation at air-liquid interfaces is established from surface-tension and particle-count studies and is the basis for anti-agitation handling guidance.

Nothing here is medical advice, and research-use compounds are not approved for human use.

At dilute concentrations, suspect adsorption before you suspect chemistry.

The relevant point is that a mass shift of plus one dalton is deamidation and plus sixteen is oxidation, so degradation is often visible in a mass spectrum if anyone looks.

Freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.

Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.

The caveat is that none of these pathways can be seen by looking at a vial, and a clear solution can be substantially degraded.

Sequence decides which pathways are even available. Check the residues.

Start with the sequence, because which pathways are available depends on which residues are present.

Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.

Adsorption losses at low concentrations are quantified in formulation studies and are the reason carrier proteins are used in dilute preparations.

Swirl, never shake. Aggregation is a handling problem more than a time problem.

Answer first: the degradation pathways worth knowing are hydrolysis, deamidation, oxidation, aggregation and adsorption, and each has a different trigger and a different mitigation.

Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.

Metal-catalysed oxidation of methionine is documented across peptide and protein formulations and is why chelators appear in some formulations.

A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.